华法林治疗脑梗死合并心房颤动患者的临床疗效及安全性评价

Evaluation on the Clinical Efficacy and Safety of Warfarin in the Treatment of Patients with Cerebral Infarction Complicated with Atrial Fibrillation

目的探讨华法林治疗脑梗死合并心房颤动患者的临床疗效与安全性。方法选择我院2017年1月至2018年1月收治的60例脑梗死合并心房颤动患者为研究对象,随机分为两组各30例。观察组采用华法林治疗,对照组采用阿司匹林治疗,观察并比较两组患者的临床疗效。结果治疗前,两组患者的各项凝血指标无统计学差异(P>0.05);治疗后,观察组患者的PT、INR均显著高于对照组(P<0.05)。治疗前,两组患者的SSS评分无统计学差异(P>0.05);治疗后,两组患者的SSS评分均显著下降,且观察组的SSS评分显著低于对照组(P<0.05)。观察组的不良反应发生率显著低于对照组(P<0.05)。结论华法林治疗脑梗死合并心房颤动患者临床疗效显著,安全性高,具有临床推广价值。

Objective To explore the clinical efficacy and safety of warfarin in the treatment of patients with cerebral infarctioncomplicated with atrial fibrillation. Methods 60 cases of patients with cerebral infarction complicated with atrial fibrillation admitted to our hospital from January 2017 to January 2018 were selected as research objects, and randomly divided into two groups, with 30 cases in each group. The observation group was treated with warfarin, while the control group was treated with aspirin. The clinical curative effects of two groups were observed and compared. Results Before treatment, no significant difference was found in the blood coagulation indicators between the two groups （P 〉0.05）; After treatment, the PT and INR of the observation group were significantly higher than those of the control group （P 〈0.05）. Before treatment, no statistical difference was found in the SSS score between the two groups （P 〉0.05）; After treatment, both groups had significantly decreased SSS score, and the SSS score of the observation group was significantly lower than that of the control group （P 〈0.05）. The incidence of adverse reactions of the observation group was significantly lower than that of the control group （P 〈0.05）. Conclusions Warfarin is effective in the treatment of patients with cerebral infarction complicated with atrial fibrillation, with high safety, which has the value of clinical promotion.